Format

Send to

Choose Destination
Atherosclerosis. 2018 Jan;268:12-18. doi: 10.1016/j.atherosclerosis.2017.11.007. Epub 2017 Nov 14.

Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease: Findings from The Atherosclerosis Risk in Communities study (ARIC).

Author information

1
Division of Cardiology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. Electronic address: parveeng@med.usc.edu.
2
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
3
University of Texas Health Sciences Center at Houston, Houston, TX, USA.
4
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
5
Division of Nephrology-Hypertension, University of California San Diego, La Jolla, CA, USA.
6
Department of Epidemiology, The Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
7
Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, TX, USA; The Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA.

Abstract

BACKGROUND AND AIMS:

Results from prospective studies evaluating the relationship between elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) activity and incident peripheral arterial disease (PAD) have been mixed. We investigated whether higher Lp-PLA2 levels are associated with increased risk of incident PAD and whether PLA2G7 gene variants, which result in lower Lp-PLA2 levels, are associated with reduced risk of incident PAD.

METHODS:

Our analysis included 9922 participants (56% female; 21% African-American; mean age 63 years) without baseline PAD at ARIC Visit 4 (1996-1998), who had Lp-PLA2 activity measured and were subsequently followed for the development of PAD, defined by occurrence of a PAD-related hospitalization, through 2012. Cox proportional hazard models were performed to determine the association of Lp-PLA2 levels and PLA2G7 gene variants with incident PAD.

RESULTS:

During a median follow-up of 14.9 years, we identified 756 incident cases of PAD. In analyses adjusting for age, race, and sex, each standard deviation increment in Lp-PLA2 activity (62 nmol/ml/min) was associated with a higher risk of developing PAD (hazard ratio (HR) 1.17; 95% confidence interval (CI) 1.09, 1.26). This association remained significant after additional adjustment for risk factors, other cardiovascular disease, and medication use, but was strongly attenuated (HR: 1.09; 95% CI 1.00, 1.20). PLA2G7 variants were not associated with a lower risk of PAD in both white carriers (HR: 1.21; 95% CI: 0.17-8.56) and African-American carriers (HR: 0.83; 95% CI: 0.41-1.67), although statistical power was quite limited for this analysis, particularly in whites.

CONCLUSIONS:

While higher Lp-PLA2 activity was associated with an increased risk for incident PAD, it is likely a risk marker largely represented by traditional risk factors.

KEYWORDS:

Epidemiology; Inflammation; Lipoprotein-associated phospholipase A(2); Peripheral artery disease

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center